MTVA
MetaVia, Inc.
NASDAQ · Healthcare · Biotechnology · US
$1.34
+6.35%Oct 28, 2026, 12:31 UTC
MetaVia announced that an abstract presenting Phase 1 clinical trial data for DA-1726 was accepted for an oral presentation at the MetaVia Inc. on November 4, 2026, in Denver.
Source:Aug 6, 2026, 20:05 UTC
MetaVia Inc. announced its financial results for the second quarter ended June 30, 2026.
Source:Jun 8, 2026, 12:31 UTC
MetaVia Inc. presented new late-breaking obesity and metabolic data at the ADA 2026 Scientific Sessions in New Orleans, Louisiana, supporting its DA-1726 and vanoglipel programs.